查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1764174

阿達木單抗市場 - 全球產業規模、佔有率、趨勢、機會和預測（按類型、治療領域、地區和競爭細分，2020-2030 年）

Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Therapeutic Area, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球阿達木單抗市場價值為 27.2 億美元，預計到 2030 年將達到 35.6 億美元，預測期內的複合年成長率為 4.80%。阿達木單抗是一種針對腫瘤壞死因子-α (TNF-a) 的單株抗體，在治療類風濕性關節炎、克隆氏症、潰瘍性結腸炎、牛皮癬和僵直性脊椎炎自體免疫疾病中起著關鍵作用。它在控制發炎和減緩疾病進展方面的療效已被證實，使其成為免疫學中廣泛採用的治療方法。市場的成長主要得益於慢性發炎疾病發生率的上升、對生物製劑治療認知的提高以及醫療保健投資的增加，尤其是在新興經濟體。儘管成熟市場持續面臨價格壓力，但全球範圍內獲得先進療法的管道和診斷率的提高預計將支持市場持續擴張。

市場概覽
預測期 2026-2030
2024年市場規模 27.2億美元
2030年市場規模 35.6億美元
2025-2030 年複合年成長率 4.80%
成長最快的領域 生物製劑
最大的市場 北美洲

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

生產成本高

主要市場趨勢

慢性病盛行率上升

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球阿達木單抗市場的影響

第5章：全球阿達木單抗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型（生物製劑、生物相似藥）
    • 依治療領域（類風濕性關節炎、乾癬性關節炎、乾癬、克隆氏症、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美阿達木單抗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲阿達木單抗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太阿達木單抗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲阿達木單抗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲阿達木單抗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球阿達木單抗市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • AbbVie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan NV
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 4996

The Global Adalimumab Market was valued at USD 2.72 billion in 2024 and is anticipated to reach USD 3.56 billion by 2030, growing at a CAGR of 4.80% over the forecast period. Adalimumab, a monoclonal antibody targeting tumor necrosis factor-alpha (TNF-a), plays a pivotal role in managing autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. Its proven efficacy in controlling inflammation and slowing disease progression has made it a widely adopted therapy in immunology. The market's growth is primarily fueled by the rising incidence of chronic inflammatory diseases, greater awareness of biologic treatments, and increased healthcare investment, particularly in emerging economies. Despite ongoing pricing pressures in mature markets, global access to advanced therapies and increased diagnosis rates are expected to support sustained market expansion.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.72 Billion
Market Size 2030USD 3.56 Billion
CAGR 2025-20304.80%
Fastest Growing SegmentBiologics
Largest MarketNorth America

Key Market Drivers

Growth in Healthcare Industry

The expanding global healthcare industry, generating annual revenues exceeding USD 4 trillion, is significantly driving the adalimumab market forward. Pharmaceuticals and biotechnology, accounting for nearly USD 850 billion, represent key contributors to this growth. As healthcare infrastructure improves across developed and emerging regions, diagnoses of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and Crohn's disease are becoming more common-boosting demand for adalimumab. Advanced diagnostics and early intervention, made possible by rising investment in healthcare systems, are leading to increased use of targeted biologics. Government support, private sector investment, and broader insurance coverage are also making high-cost treatments more accessible. With global healthcare spending reaching USD 9.8 trillion in 2021, representing over 10% of global GDP, emerging markets are witnessing improved patient access to biologics through expanded hospital networks and reform-driven health systems. As a result, adalimumab continues to benefit from these advancements, cementing its position as a frontline treatment in immunology.

Key Market Challenges

High Cost of Production

A key challenge in the global adalimumab market is the high cost of biologic drug production. The manufacturing of adalimumab, a complex monoclonal antibody, involves intricate biotechnological methods that require substantial investment in specialized infrastructure, skilled personnel, and regulatory compliance. The use of living cells in the development process, combined with tightly controlled manufacturing conditions, contributes to elevated production costs. Critical stages such as cell culture, purification, and formulation are both time-consuming and resource-intensive. Furthermore, risks such as batch failure and the rigorous validation requirements further strain cost efficiency. These high production costs pose a barrier for manufacturers, particularly when attempting to scale or introduce biosimilars in competitive markets.

Key Market Trends

Rising Prevalence of Chronic Diseases

The growing incidence of autoimmune and inflammatory diseases represents a significant trend shaping the adalimumab market. Conditions like rheumatoid arthritis, ulcerative colitis, psoriasis, and Crohn's disease are becoming more prevalent, driven by aging populations, sedentary lifestyles, and environmental triggers. As these chronic conditions often require long-term treatment, demand for reliable and effective biologics continues to rise. Adalimumab, with its broad therapeutic indications and established clinical profile, remains a preferred option for managing chronic inflammation. It was the first fully human monoclonal antibody to receive approval for rheumatoid arthritis and has since proven its safety and efficacy in long-term use. This growing reliance on biologics underscores the sustained role of adalimumab in immunological treatment strategies worldwide.

Key Market Players

  • AbbVie Inc.
  • Pfizer, Inc.
  • Amgen Inc.
  • Novartis AG
  • Torrent Pharmaceuticals Ltd.
  • Cadila Healthcare Limited
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.
  • Hetero Biopharma Ltd
  • Samsung Bioepis Co Ltd.

Report Scope

In this report, the Global Adalimumab Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Adalimumab Market, By Type:

  • Biologics
  • Biosimilars

Adalimumab Market, By Therapeutic Area:

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Psoriasis
  • Crohn's Disease
  • Others

Adalimumab Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Adalimumab Market.

Available Customizations

Global Adalimumab Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Adalimumab Market

5. Global Adalimumab Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Biologics, Biosimilars)
    • 5.2.2. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Adalimumab Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Therapeutic Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Adalimumab Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Therapeutic Area
    • 6.3.2. Mexico Adalimumab Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Therapeutic Area
    • 6.3.3. Canada Adalimumab Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Therapeutic Area

7. Europe Adalimumab Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Therapeutic Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Adalimumab Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Therapeutic Area
    • 7.3.2. Germany Adalimumab Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Therapeutic Area
    • 7.3.3. United Kingdom Adalimumab Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Therapeutic Area
    • 7.3.4. Italy Adalimumab Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Therapeutic Area
    • 7.3.5. Spain Adalimumab Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Adalimumab Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Adalimumab Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Therapeutic Area
    • 8.3.2. India Adalimumab Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Therapeutic Area
    • 8.3.3. South Korea Adalimumab Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Therapeutic Area
    • 8.3.4. Japan Adalimumab Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Therapeutic Area
    • 8.3.5. Australia Adalimumab Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Therapeutic Area

9. South America Adalimumab Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Therapeutic Area
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Adalimumab Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Therapeutic Area
    • 9.3.2. Argentina Adalimumab Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Therapeutic Area
    • 9.3.3. Colombia Adalimumab Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Therapeutic Area

10. Middle East and Africa Adalimumab Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Therapeutic Area
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Adalimumab Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Therapeutic Area
    • 10.3.2. Saudi Arabia Adalimumab Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Therapeutic Area
    • 10.3.3. UAE Adalimumab Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Adalimumab Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. AbbVie Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Pfizer, Inc.
  • 16.3. Amgen Inc.
  • 16.4. Novartis AG
  • 16.5. Torrent Pharmaceuticals Ltd.
  • 16.6. Cadila Healthcare Limited
  • 16.7. Boehringer Ingelheim International GmbH
  • 16.8. Mylan N.V.
  • 16.9. Hetero Biopharma Ltd
  • 16.10. Samsung Bioepis Co Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer